Cartesian Therapeutics (RNAC) Non-Current Debt (2016 - 2023)
Historic Non-Current Debt for Cartesian Therapeutics (RNAC) over the last 8 years, with Q2 2023 value amounting to $13.8 million.
- Cartesian Therapeutics' Non-Current Debt fell 3908.72% to $13.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.8 million, marking a year-over-year decrease of 3908.72%. This contributed to the annual value of $17.8 million for FY2022, which is 959.18% down from last year.
- According to the latest figures from Q2 2023, Cartesian Therapeutics' Non-Current Debt is $13.8 million, which was down 3908.72% from $16.2 million recorded in Q1 2023.
- In the past 5 years, Cartesian Therapeutics' Non-Current Debt registered a high of $25.0 million during Q1 2022, and its lowest value of $6.4 million during Q2 2020.
- Over the past 4 years, Cartesian Therapeutics' median Non-Current Debt value was $21.3 million (recorded in 2021), while the average stood at $20.0 million.
- Per our database at Business Quant, Cartesian Therapeutics' Non-Current Debt skyrocketed by 25557.45% in 2021 and then plummeted by 3908.72% in 2023.
- Quarter analysis of 4 years shows Cartesian Therapeutics' Non-Current Debt stood at $24.8 million in 2020, then fell by 20.65% to $19.7 million in 2021, then fell by 9.59% to $17.8 million in 2022, then fell by 22.48% to $13.8 million in 2023.
- Its Non-Current Debt was $13.8 million in Q2 2023, compared to $16.2 million in Q1 2023 and $17.8 million in Q4 2022.